FOR IMMEDIATE RELEASE

News Release

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

*Patient’s own tissue naturally turn device into living heart valves and may reduce need for re-interventions*

EINDHOVEN, The Netherlands/ZURICH, Switzerland - July 8, 2021 – Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To date, pediatric patients requiring right ventricular outflow tract (RVOT) reconstruction have been successfully implanted as part of the global, FDA-approved Xplore2/Pivotal study. RVOT reconstruction is a procedure needed to correct certain congenital heart defects.

Following implantation, Xeltis’ synthetic restorative pulmonary heart valves evolve into fully functioning, natural heart valves through colonization by the patient’s own tissue. The implants’ porous micro-structure enables the patient’s own tissue to populate it and naturally form a new heart valve that takes over functionality over time. Meanwhile, the original synthetic structure, made from electrospun polymers, resorbs into the body.

“Regenerating living heart valves in patients requiring RVOT reconstruction may substantially change their quality of life,” said David Morales, M.D., Director, Congenital Heart Surgery, Cincinnati Children’s Hospital and Professor, Department of Pediatrics at University of Cincinnati, who is global principal investigator of the trial. “A device that has longer life-span and that potentially grows with the patient would reduce repeated interventions and the physical and psychological burden associated to them.”

*Xplore2/Pivotal* is a prospective, non-randomized clinical study to assess safety and efficacy of the restorative pulmonary valve in up to 50 patients undergoing RVOT reconstruction. The U.S. FDA-approved Investigational Device Exemption trial will be conducted in up to 15 centers in the U.S., Europe and Asia. The implanted patients will be followed-up for five years.

“Data from 18 patients implanted with the Xeltis restorative pulmonary valve as part of other ongoing clinical trials are very promising,” said Professor Tomasz Mroczek, cardio-thoracic surgeon at the Polish-American Children’s Hospital in Krakow, Poland. Professor Mroczek implanted the first patient of the Xplore2/Pivotal trial and had also previously implanted three pediatric patients as part of the ongoing Xplore-1 study for the Xeltis pulmonary valve. “The positive safety profile and performance seen in over 60 patient-years of follow-up provide strong indication of a potential best-in-class device to reduce re-operations and improve lives for patients.”

The two-year results from the Xplore-1 trial conducted in 12 patients in Europe and Asia and the one-year data from the U.S. FDA-approved Early Feasibility Study (EFS) Xplore-2 in six patients have been recently published in the peer-reviewed journal *Frontiers in Cardiovascular Medicine.*

---

Xeltis

outcomes from patients up to four years post-surgery confirm consistently low repeat re-intervention rates and offer promising signs of the technology’s superior potential.²

“The Xeltis pulmonary heart valve is the most advanced heart valve with regenerative properties based only on a biocompatible synthetic structure and the first ever synthetic restorative valve to enter a pivotal trial,” said Eliane Schutte, Xeltis CEO. “We are extremely proud of our clinical program progression, which also includes two small diameter blood vessel applications. All our regenerative devices promise to offer solutions that overcome the limitations of existing technologies – or the complete lack of them.”

In addition to its restorative pulmonary valve, Xeltis has developed the first-ever restorative synthetic coronary artery bypass graft (CABG) to have shown successful long-term results in long preclinical trials and the first-ever restorative synthetic vascular access graft for patients that need dialysis.¹

- End -

Notes to editors
About RVOT
One in 100 babies are born with a heart defect in the USA,³,⁴ Congenital Heart Disease (CHD) is the most common type of birth defects,⁵ of which 15-20 percent generally affect the right ventricular outflow tract (RVOT).² These defects reduce or stop the blood flowing to the pulmonary arteries and include severe conditions, such as tetralogy of Fallot, truncus arteriosus, pulmonary atresia, transposition of great arteries and pulmonary stenosis. Defective RVOTs require an open-heart surgical intervention called RVOT reconstruction, which normally involves the replacement of the pulmonary valve.

About Cardiovascular Restoration
Currently available options for heart valve replacement are either short-lived or may need long-term medication.⁵,⁷ Xeltis’ devices naturally evolve into living heart valves within the body, through colonization by patient’s own tissue to overcome the limitation of existing options. This therapeutic process is called endogenous tissue restoration, or ETR. With ETR, the Xeltis heart valve works like a ‘home’ for patient’s tissue that develops as part of natural healing. The new tissue turns the device into a new, living and fully functional heart valve. As the new living valve takes over functionality, the original synthetic structure gradually absorbs within the body.

About Xplore2/Pivotal trial
Xplore2/Pivotal is an FDA-approved prospective, non-randomized, open label clinical study of Xeltis’ restorative pulmonary heart valve in patients requiring right ventricular outflow tract (RVOT) reconstruction. The trial will enroll up to 50 patients aged 2-22 years in up to 15 sites in USA, Europe and Asia, which currently include: Cincinnati Children’s Hospital, Cincinnati (OH); University of Texas Southwestern Medical Center, Dallas (TX); Children’s Hospital Colorado, Aurora (CO); Children’s Hospital Los Angeles (CA); University Children’s Hospital, Krakow (Poland); National Cardiology Hospital Sofia (Bulgaria); National Heart Institute, Kuala Lumpur (Malaysia). For further information: www.xplore2MD.com; www.clinicaltrials.gov Identifier: NCT03022708.

---

² Xeltis data on file
⁵ Center for Disease Control and Prevention. Data and Statistics on Congenital Heart Defects. Retrieved online on 24/06/2021 on https://www.cdc.gov/ncbddd/heartdefects/data.html#References
⁷ Rüffer A. et al. Mid-term experience with the Hancock porcine-valved Dacron conduit for right ventricular outflow tract reconstruction. Eur J Cardiothorac Surg. 2012 Dec;42(6)
About Xeltis
A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices comprise heart valves and small diameter blood vessels for coronary artery bypass graft (CABG) surgery and for hemodialysis vascular access. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs and it currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds Kurma Partners, LSP, VI Partners and Ysios Capital as well as a number of private investors.

Media Contacts:
Laura Bertossi Monti
Xeltis
+44 75544 25402
laura.monti@xeltis.com

CAUTION: The Xeltis technology is an investigational device and NOT approved for sale.